Abstract:High mobility group protein B1 (HMGB1) has been implicated as an important mediator in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD). However, the expression of HMGB1 in plasma and sputum of patients with asthma and COPD across disease severity needs to be defined. The objective of the study was to examine the induced sputum and plasma concentrations of HMGB1 in COPD and asthmatic patients to determine differences in HMGB1 levels between these diseases and their relationship with airway obstruction and inflammatory patterns. A total of 147 participants were enrolled in this study. The participants included 34 control subjects, 61 patients with persistent asthma (according to the Global Initiative for Asthma [GINA] guidelines) and 47 patients with stable COPD (stratified by Global Initiative for Chronic Obstructive Lung Disease [GOLD] status). Spirometry was performed before sputum induction. HMGB1 levels in induced sputum and plasma were determined by enzyme-linked immunosorbent assay. Sputum and plasma concentrations of HMGB1 in patients with asthma and COPD were significantly higher than concentrations in control subjects and were significantly negatively correlated with forced expiratory volume in 1 s (FEV 1 ), FEV 1 (% predicted) in all 147 participants. The levels of HMGB1 in induced sputum of COPD patients were significantly higher than those of asthma patients and healthy controls ( P < 0.001). This difference was present even after adjusting for sex, age, smoking status, daily dose of inhaled corticosteroids and disease severity. There were no significant differences in HMGB1 levels between patients with eosinophilic and noneosinophilic asthma. HMGB1 levels in asthmatic and COPD patients were positively correlated with neutrophil counts and percentage of neutrophils. In multivariate analysis, the two diseases (asthma and COPD) and disease severity were independent predictors of sputum HMGB1, but not smoking, age or use of inhaled corticosteroids. In conclusion, these data support a potential role for HMGB1 as a biomarker and diagnostic tool for the differential diagnosis of asthma and COPD. The importance of this observation on asthma and COPD mechanisms and outcomes should be further investigated in large prospective studies.

HMGB1-induced ILC2s Activate Dendritic Cells by Producing IL-9 in Asthmatic Mouse Model.

HMGB1 Regulates T Helper 2 and T Helper17 Cell Differentiation Both Directly and Indirectly in Asthmatic Mice.

HMGB1 was negatively regulated by HSF1 and mediated the TLR4/MyD88/NF-κB signal pathway in asthma

HMGB1 is a promising therapeutic target for asthma

Recombinant HMGB1 A box protein inhibits Th17 responses in mice with neutrophilic asthma by suppressing dendritic cell-mediated Th17 polarization

Anti-HMGB1 Neutralizing Antibody Ameliorates Neutrophilic Airway Inflammation by Suppressing Dendritic Cell-Mediated Th17 Polarization

Lung Dysfunction in a Mouse Model of Inflammation is Dependent on T-cell-independent IL-13 Expression (54.18)

The absence of IL-9 reduces allergic airway inflammation by reducing ILC2, Th2 and mast cells in murine model of asthma

ATP/P2X7-NLRP3 Axis of Dendritic Cells Participates in the Regulation of Airway Inflammation and Hyper-Responsiveness in Asthma by Mediating HMGB1 Expression and Secretion.

House dust mite allergen directly activates ILC2 cells via the TLR4 signaling pathway in allergic airway diseases

HMGB1 Binding to the RAGE Receptor Contributes to the Pathogenesis of Asthma

MBD2 Regulates Th17 Cell Differentiation and Experimental Severe Asthma by Affecting IRF4 Expression

B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3

[Expression of high mobility group box-1 in the lung tissue and BALF of asthmatic mice and the influence of dexamethasone].

Innate-like Lymphocytes and Innate Lymphoid Cells in Asthma

HMGB1/RAGE Signaling Regulates Th17/IL-17 and Its Role in Bronchial Epithelial-Mesenchymal Transformation

Interferon-γ Stimulates Interleukin-27 Derived from Dendritic Cells to Regulate Th9 Differentiation through STAT1/3 Pathway

High Mobility Group Protein Bl (HMGB1) in Asthma: Comparison of Patients with Chronic Obstructive Pulmonary Disease and Healthy Controls

IL-13+ Type 2 Innate Lymphoid Cells Correlate with Asthma Control Status and Treatment Response.

Roles of Th17 Lymphocytes and Inflammatory Cytokines in Airway Inflammation Exacerbation of Murine Asthmatic Model

High-mobility group box-1 protein from CC10+ club cells promotes type 2 response in the later stage of respiratory syncytial virus infection.